Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma

R. Ishibashi, Naoyuki Shigematsu, T. Kawada, H. Ito, T. Nakayama, Y. Andou, A. Kubo, M. Tachibana

Research output: Contribution to journalArticle

Abstract

The standard treatment for an invasive bladder cancer is radical surgery; however, the quality of life of the patients who undergo total cystectomy is unfavorable even when the ileal conduits were constructed. We carried out a bladder-conserving treatment for 8 bladder cancer patients by using a hyperfractionated radiotherapy together with low dose of cis-platinum or carboplatinum daily as a radiosensitizer following trans-urethral tumor resection and neoadjuvant chemotherapy. Cystoscopic findings and biopsies at one month after completing radiation showed complete remission (CR) and partial response (PR) for 5 and 3 patients, respectively. All of the PR cases had T4 tumors and the patients with tumors smaller than T3 and without lymph node metastasis achieved CR. All patients completed radiotherapy without acute severe complications. Six patients have remained alive for more than 10 months and radiation induced late complications such as bladder or intestinal insufficiency have not been observed thus far.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalJournal of JASTRO
Volume9
Issue number2
Publication statusPublished - 1997

Fingerprint

Urinary Bladder
Radiotherapy
Carcinoma
Drug Therapy
Urinary Bladder Neoplasms
Radiation
Neoplasms
Urinary Diversion
Cystectomy
Cisplatin
Lymph Nodes
Quality of Life
Neoplasm Metastasis
Biopsy
Therapeutics

Keywords

  • Bladder cancer
  • Hyperfractionated radiotherapy
  • Radiosensitizer

ASJC Scopus subject areas

  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Ishibashi, R., Shigematsu, N., Kawada, T., Ito, H., Nakayama, T., Andou, Y., ... Tachibana, M. (1997). Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma. Journal of JASTRO, 9(2), 125-130.

Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma. / Ishibashi, R.; Shigematsu, Naoyuki; Kawada, T.; Ito, H.; Nakayama, T.; Andou, Y.; Kubo, A.; Tachibana, M.

In: Journal of JASTRO, Vol. 9, No. 2, 1997, p. 125-130.

Research output: Contribution to journalArticle

Ishibashi, R, Shigematsu, N, Kawada, T, Ito, H, Nakayama, T, Andou, Y, Kubo, A & Tachibana, M 1997, 'Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma', Journal of JASTRO, vol. 9, no. 2, pp. 125-130.
Ishibashi, R. ; Shigematsu, Naoyuki ; Kawada, T. ; Ito, H. ; Nakayama, T. ; Andou, Y. ; Kubo, A. ; Tachibana, M. / Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma. In: Journal of JASTRO. 1997 ; Vol. 9, No. 2. pp. 125-130.
@article{dbe5500f706c4818bf918fa441ade064,
title = "Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma",
abstract = "The standard treatment for an invasive bladder cancer is radical surgery; however, the quality of life of the patients who undergo total cystectomy is unfavorable even when the ileal conduits were constructed. We carried out a bladder-conserving treatment for 8 bladder cancer patients by using a hyperfractionated radiotherapy together with low dose of cis-platinum or carboplatinum daily as a radiosensitizer following trans-urethral tumor resection and neoadjuvant chemotherapy. Cystoscopic findings and biopsies at one month after completing radiation showed complete remission (CR) and partial response (PR) for 5 and 3 patients, respectively. All of the PR cases had T4 tumors and the patients with tumors smaller than T3 and without lymph node metastasis achieved CR. All patients completed radiotherapy without acute severe complications. Six patients have remained alive for more than 10 months and radiation induced late complications such as bladder or intestinal insufficiency have not been observed thus far.",
keywords = "Bladder cancer, Hyperfractionated radiotherapy, Radiosensitizer",
author = "R. Ishibashi and Naoyuki Shigematsu and T. Kawada and H. Ito and T. Nakayama and Y. Andou and A. Kubo and M. Tachibana",
year = "1997",
language = "English",
volume = "9",
pages = "125--130",
journal = "Journal of JASTRO",
issn = "1040-9564",
publisher = "Editorial Board of JASTRO",
number = "2",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy and hyperfractionated radiation therapy for the urinary bladder carcinoma

AU - Ishibashi, R.

AU - Shigematsu, Naoyuki

AU - Kawada, T.

AU - Ito, H.

AU - Nakayama, T.

AU - Andou, Y.

AU - Kubo, A.

AU - Tachibana, M.

PY - 1997

Y1 - 1997

N2 - The standard treatment for an invasive bladder cancer is radical surgery; however, the quality of life of the patients who undergo total cystectomy is unfavorable even when the ileal conduits were constructed. We carried out a bladder-conserving treatment for 8 bladder cancer patients by using a hyperfractionated radiotherapy together with low dose of cis-platinum or carboplatinum daily as a radiosensitizer following trans-urethral tumor resection and neoadjuvant chemotherapy. Cystoscopic findings and biopsies at one month after completing radiation showed complete remission (CR) and partial response (PR) for 5 and 3 patients, respectively. All of the PR cases had T4 tumors and the patients with tumors smaller than T3 and without lymph node metastasis achieved CR. All patients completed radiotherapy without acute severe complications. Six patients have remained alive for more than 10 months and radiation induced late complications such as bladder or intestinal insufficiency have not been observed thus far.

AB - The standard treatment for an invasive bladder cancer is radical surgery; however, the quality of life of the patients who undergo total cystectomy is unfavorable even when the ileal conduits were constructed. We carried out a bladder-conserving treatment for 8 bladder cancer patients by using a hyperfractionated radiotherapy together with low dose of cis-platinum or carboplatinum daily as a radiosensitizer following trans-urethral tumor resection and neoadjuvant chemotherapy. Cystoscopic findings and biopsies at one month after completing radiation showed complete remission (CR) and partial response (PR) for 5 and 3 patients, respectively. All of the PR cases had T4 tumors and the patients with tumors smaller than T3 and without lymph node metastasis achieved CR. All patients completed radiotherapy without acute severe complications. Six patients have remained alive for more than 10 months and radiation induced late complications such as bladder or intestinal insufficiency have not been observed thus far.

KW - Bladder cancer

KW - Hyperfractionated radiotherapy

KW - Radiosensitizer

UR - http://www.scopus.com/inward/record.url?scp=0030753092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030753092&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030753092

VL - 9

SP - 125

EP - 130

JO - Journal of JASTRO

JF - Journal of JASTRO

SN - 1040-9564

IS - 2

ER -